#1 Startup Dataset
Growth rates, revenue data, direct competitors and contact details.
Antti Vuolanto Email
CEO . Herantis Pharma
Espoo,
LocationPrimary Email
How to contact Antti Vuolanto
Join and see Antti's contact info for free!Current Roles
Employees:
23Revenue:
$3.6MAbout
Herantis Pharma is a publicly listed (HRTIS) innovative clinical stage biotech company with a diverse pipeline of pioneering investigational therapeutics looking to modify the course of debilitating nervous system and lymphatic diseases and break the boundaries of standard therapeutic approaches. Leveraging deep scientific brilliance in protein dysregulation for neurodegenerative diseases, and growth stimulation in lymphatic diseases, Herantis is advancing a rich pipeline of regenerative biological and gene therapies for high impact diseases. These include i. CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson's disease and other neurodegenerative diseases, and ii. Lymfactin® VEGF-C gene therapy for restoring lymphatic structure and function for the treatment of oncology related secondary Lymphedema and other lymphatic based diseases. Herantis is pursuing disease modifying treatments that slow, stop, or even reverse the course of diseases, and bring much needed innovation to these underserved diseases. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden. Follow us @HerantisPharma on Twitter!Herantis Pharma Address
Bertel Jungin aukio 1Espoo, null